Group 1 - Company repurchased 535,000 shares at approximately HKD 5 per share, totaling over HKD 2.68 million on December 11, with a cumulative repurchase of nearly 2 million shares in December, exceeding HKD 10 million [1] - The repurchase actions indicate that the company believes its stock is undervalued, and such actions should be supported by improvements in fundamentals [1] - The latest interim financial report for FY2026 shows total revenue of RMB 358 million, an 8.7% year-on-year increase, with adjusted EBITDA of approximately RMB 54 million, doubling from the previous year [1] Group 2 - The company has provided comprehensive solutions for "Hui Min Bao" projects in various regions, serving over 40 million insured users [2] - The "Shenzhen Hui Min Bao," operated by the company, has included all 19 innovative drugs from the first version of the commercial insurance innovative drug catalog in its coverage for the 2025 fiscal year [2] - The company offers full-chain support for pharmaceutical companies, enhancing R&D efficiency and providing critical services for market access and pricing strategies [2]
医渡科技12月以来6次回购 累计斥资超1000万港元